|
🐜
|
Obinutuzumab for the First‐Line Treatment of Follicular Lymphoma
18 auth.
R. Marcus,
A. Davies,
K. Ando,
W. Klapper,
Stephen Samuel Opat,
C. Owen,
E. Phillips,
R. Sangha,
R. Schlag,
J. Seymour,
...
W. Townsend,
M. Trněný,
M. Wenger,
G. Fingerle-Rowson,
K. Rufibach,
T. Moore,
M. Herold,
W. Hiddemann
|
9 |
2017 |
9
🐜
|
|
🐜
|
The Absence of Human Equilibrative Nucleoside Transporter 1 Is Associated with Reduced Survival in Patients With Gemcitabine-Treated Pancreas Adenocarcinoma
9 auth.
J. Spratlin,
R. Sangha,
D. Glubrecht,
L. Dabbagh,
J. Young,
C. Dumontet,
...
C. Cass,
R. Lai,
J. Mackey
|
8 |
2004 |
8
🐜
|
|
🐜
|
Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
21 auth.
M. C. Palanca-Wessels,
M. Czuczman,
G. Salles,
S. Assouline,
L. Sehn,
I. Flinn,
M. Patel,
R. Sangha,
A. Hagenbeek,
R. Advani,
...
H. Tilly,
O. Casasnovas,
O. Press,
Sreeni Yalamanchili,
Robert Kahn,
Randall Dere,
D. Lu,
Surai Jones,
Cheryl Jones,
Y. Chu,
F. Morschhauser
|
8 |
2015 |
8
🐜
|
|
🐜
|
EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4–Positive Solid Tumors, Including Metastatic Urothelial Carcinoma
20 auth.
J. Rosenberg,
S. Sridhar,
Jingsong Zhang,
David C. Smith,
D. Ruether,
T. Flaig,
J. Baranda,
J. Lang,
E. Plimack,
R. Sangha,
...
E. Heath,
J. Merchan,
D. Quinn,
S. Srinivas,
M. Milowsky,
Chunzhang Wu,
E. Gartner,
Peiying Zuo,
A. Melhem-Bertrandt,
D. Petrylak
|
7 |
2020 |
7
🐜
|
|
🐜
|
First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small Cell Lung Cancer: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial.
39 auth.
L. Paz-Ares,
S. Ramalingam,
T. Ciuleanu,
Jong-Seok Lee,
L. Urban,
R. B. Caro,
Keunchil Park,
H. Sakai,
Y. Ohe,
M. Nishio,
C. Audigier-Valette,
J. Burgers,
A. Płużański,
R. Sangha,
C. Gallardo,
...
M. Takeda,
H. Linardou,
L. Lupinacci,
K. Lee,
C. Caserta,
M. Provencio,
E. Carcereny,
G. Otterson,
M. Schenker,
B. Żurawski,
A. Alexandru,
A. Vergnenègre,
J. Raimbourg,
K. Feeney,
Sang-We Kim,
H. Borghaei,
K. O'Byrne,
M. Hellmann,
A. Memaj,
F. Nathan,
J. Bushong,
P. Tran,
J. Brahmer,
M. Reck
|
7 |
2021 |
7
🐜
|
|
🐜
|
Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial.
21 auth.
M. Reck,
M. Schenker,
K. Lee,
M. Provencio,
M. Nishio,
K. Leśniewski-Kmak,
R. Sangha,
Samreen I. Ahmed,
J. Raimbourg,
K. Feeney,
...
R. Corre,
F. Franke,
E. Richardet,
J. Penrod,
Yong Yuan,
F. Nathan,
P. Bhagavatheeswaran,
M. Derosa,
F. Taylor,
R. Lawrance,
J. Brahmer
|
7 |
2019 |
7
🐜
|
|
🦁
|
L-BLP25: A Peptide Vaccine Strategy in Non–Small Cell Lung Cancer
R. Sangha,
C. Butts
|
7 |
2007 |
7
🦁
|
|
🐜
|
Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227
24 auth.
J. Brahmer,
Jong-Seok Lee,
T. Ciuleanu,
R. Bernabé Caro,
M. Nishio,
L. Urban,
C. Audigier-Valette,
L. Lupinacci,
R. Sangha,
A. Płużański,
...
J. Burgers,
M. Mahave,
Samreen Ahmed,
A. Schoenfeld,
L. Paz-Ares,
M. Reck,
H. Borghaei,
K. O'Byrne,
Ravi G. Gupta,
J. Bushong,
Li Li,
S. Blum,
Laura J. Eccles,
S. Ramalingam
|
7 |
2022 |
7
🐜
|
|
🐜
|
Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial.
24 auth.
P. Ellis,
F. Shepherd,
M. Millward,
F. Perrone,
L. Seymour,
Geoffrey Liu,
Sophie Sun,
B. Cho,
A. Morabito,
N. Leighl,
...
M. Stockler,
Christopher W. Lee,
R. Wierzbicki,
V. Cohen,
N. Blais,
R. Sangha,
A. Favaretto,
Jin-Hyoung Kang,
M. Tsao,
Carolyn F. Wilson,
Z. Goldberg,
K. Ding,
G. Goss,
P. Bradbury
|
6 |
2014 |
6
🐜
|
|
🐜
|
A phase I open-labeled, single-arm, dose-escalation, study of dichloroacetate (DCA) in patients with advanced solid tumors
8 auth.
Q. Chu,
R. Sangha,
J. Spratlin,
L. Vos,
J. Mackey,
A. Mcewan,
...
P. Venner,
E. Michelakis
|
6 |
2015 |
6
🐜
|
|
🐜
|
Gastric Acid suppression is associated with decreased erlotinib efficacy in non-small-cell lung cancer.
11 auth.
M. Chu,
Sunita Ghosh,
C. Chambers,
N. Basappa,
C. Butts,
Q. Chu,
...
D. Fenton,
A. Joy,
R. Sangha,
M. Smylie,
M. Sawyer
|
6 |
2015 |
6
🐜
|
